Uterine Junctional Zone and Its Relation to Adverse Obstetrical Outcomes in Assisted Reproductive Technology

Sponsor
Centro Hospitalar Lisboa Norte (Other)
Overall Status
Recruiting
CT.gov ID
NCT05763498
Collaborator
(none)
200
3
29.2
66.7
2.3

Study Details

Study Description

Brief Summary

The junctional zone (JZ) is an internal layer of the myometrium, with unique characteristics that allow its visualization as a hypoechogenic structure in three-dimensional (3D) ultrasound.

While there is a growing realization that the origins of major obstetrical complications associated with defective deep placentation, such as pre-term labour, fetal growth restriction and pre-eclampsia, may lie in the very early pregnancy events, the underlying mechanisms are not understood.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    During pregnancy, unique vascular changes occur, associated with decidualization of the maternal tissues in response to trophoblast invasion, first in the endometrium and subsequently in the myometrial JZ. The JZ broadly represents the inner third of the myometrium that, together with its overlying endometrium, is involved in placentation.

    Defective deep placentation, defined by the absent or incomplete remodelling of the JZ segment of the spiral arteries, may be associated with a spectrum of obstetrical complications, ranging from late miscarriage and pre-term labour to fetal growth restriction and pre-eclampsia.

    Thus, the primary site of vascular pathology in pregnancies lies not in the placenta or decidua but in the JZ. To understand how impaired remodelling of the myometrial JZ prior to conception may predispose to subsequent defective deep placentation, it is important to first describe the structural and functional changes in the JZ at the time of embryo implantation, and subsequently analyse the distinguishing features of defective deep placentation associated with different pregnancy disorders.

    Thus, non-invasive assessment of the JZ prior to conception may turn out to be useful in identifying those women at risk of major obstetrical complications.

    This project aims to evaluate the relationship between the characteristics of the ZJ in 3D ultrasound, and major adverse obstetrical outcomes in assisted reproductive technology (ART) treatments, namely in vitro fertilization cycles, intracytoplasmic sperm injection and frozen embryo transfer (FET).

    In a prospective and observational study with the inclusion of 200 cases, a 3D ultrasound will be performed on the day on which the final oocyte maturation is triggered or, on FET, on the day prior to the administration of progesterone.

    After the quality of visualization of the JZ is classified, its thickness will be measured and described as regular, irregular or interrupted.

    The volume of the ZJ will be obtained by subtracting the endometrial volume from the volume of the junctional zone and the endometrium.

    These characteristics will be related to major obstetrical adverse outcomes: pre-eclampsia, pre-term labour and fetal growth restriction. The relation with a high-risk first trimester screening for pre-eclampsia will also be accessed.

    After explaining the study and obtaining written consent, a 3D ultrasound will be performed for uterine evaluation, on the day of the final oocyte maturation trigger in cases of IVF / ICSI. In cases of FET, the ultrasound evaluation will be carried out on the day before the start of the luteal phase support.

    All ultrasounds will be performed in a standardized manner by the same operator. With an empty bladder, in a lithotomy position, a 2D transvaginal ultrasound will be performed using a GE Voluson 730 Expert® ultrasound, with an endovaginal probe with a 4-8MHz frequency. Identification of endometriosis lesions or acquired uterine abnormalities such as leiomyomas or adenomyosis will be exclusion criteria. After evaluating the number and maximum dimension of the ovarian follicles and the endometrial thickness, the three-dimensional volume box will be placed to encompass the entire uterus in longitudinal section, with minimal inclusion of para-uterine structures. A maximum acquisition angle of 90º and maximum quality will be used. To minimize artifacts, during the acquisition both the probe and the woman must remain immobile, being asked to hold their breath. Then, a three-dimensional volume will be generated by automatic 360º rotation of the transducer. For each case, two volumes will always be obtained.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    200 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Uterine Junctional Zone Evaluation on 3D Ultrasound and Its Relation to Major Adverse Obstetrical Outcomes in Assisted Reproductive Technology
    Actual Study Start Date :
    Feb 24, 2023
    Anticipated Primary Completion Date :
    Feb 28, 2025
    Anticipated Study Completion Date :
    Jul 31, 2025

    Outcome Measures

    Primary Outcome Measures

    1. Pre-eclampsia [40 weeks]

      Pre-eclampsia rate

    2. pre-term labour [37 weeks]

      pre-term labour rate

    3. Fetal growth restriction [40 weeks]

      Fetal growth restriction rate

    Secondary Outcome Measures

    1. High-risk first trimester screening for pre-eclampsia [12 weeks]

      High-risk first trimester screening for pre-eclampsia rate

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 40 Years
    Sexes Eligible for Study:
    Female
    Inclusion Criteria:
    • Women followed in the infertility clinic aged between 18 and 42 years in cycles of IVF, ICSI or endometrial preparation for frozen embryo transfer
    Exclusion Criteria:
    • Myomas

    • adenomyosis

    • endometriosis

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Hospital Central do Funchal Funchal Madeira Portugal 9000
    2 Departamento de Obstetricia, Ginecologia e Medicina da Reprodução Lisbon Portugal 1600
    3 Centro Hospitalar Universitário Lisboa Norte Lisbon Portugal

    Sponsors and Collaborators

    • Centro Hospitalar Lisboa Norte

    Investigators

    • Principal Investigator: Isabel B Pereira, M.D, Centro Hospitalar Lisboa Norte

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Isabel Pereira, M.D., Centro Hospitalar Lisboa Norte
    ClinicalTrials.gov Identifier:
    NCT05763498
    Other Study ID Numbers:
    • JZ OO
    First Posted:
    Mar 10, 2023
    Last Update Posted:
    Mar 10, 2023
    Last Verified:
    Mar 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Isabel Pereira, M.D., Centro Hospitalar Lisboa Norte
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 10, 2023